Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2011

View Archived Issues

Sangamo BioSciences provides update on product pipeline

UCB claims new PI3K inhibitors

Ortho-McNeil-Janssen Pharma patents new gamma-secretase modulators

Helix BioPharma submits IND to FDA for first-in-human study of L-DOS47

New cannabinoid CB1 receptor antagonists presented by sanofi-aventis

Ferrer claims new melatonin MT1 receptor agonists

Studies investigate effects of intranasal oxytocin in schizophrenia, depression and autism

AM-095 displays antifibrotic activity in vivo

JTT-305 shows bone anabolic effects in vivo

HPRG-induced downregulation of PlGF shows anticancer potential

BIND Biosciences begins phase I study of BIND-014 in cancer

Topica begins enrollment in phase I/IIa luliconazole trial in onychomycosis

Ablynx reports follow-up data from phase I trial of ALX-0141

AstraZeneca and SCRI join to develop targeted anticancer agent

Concert Pharma claims new PDE4 inhibitors and TNF-alpha production suppressors

Allozyne completes phase Ia trial of AZ-01 for multiple sclerosis

New inhibitors of HCV NS5A developed at Enanta Pharma

Omthera reports bioavailability data from ECLIPSE trial of Epanova

Sumavel DosePro obtains marketing approval in Germany and U.K.

FDA issues positive feedback for design of phase III Davanat trial in colorectal cancer

Peregrine Pharma begins phase II bavituximab trial in hepatitis C

Enrollment begins in phase III trial of sapacitabine as front-line AML therapy

Antigenics becomes Agenus and expands product portfolio

BioMarin begins phase I/II trial of BMN-673 in genetically defined cancers

Curis selects CUDC-907 as development candidate for targeted cancer program

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...